Roxin Pharmaceuticals: plans to transfer 20% of the equity of Luo'an Company to Helix for $512.5 million.

Luo Xin Pharmaceuticals announced that its subsidiary Shandong Luo Xin plans to transfer 20% of its shares in Luo Xin Anruo Vita Pharmaceutical Co., Ltd. to Helix Healthcare B.V. for $5.125 million. Prior to this share transfer, Shandong Luo Xin held 70% of shares in Luo An Company. After this share transfer is completed, Shandong Luo Xin will hold 50% of shares in Luo An Company, and Luo An Company will no longer be included in the company's consolidated financial statements.